Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis

NCT00726479 | Withdrawn Phase 2

• 2 other identifiers: 1219.4EUDRACT2007-003742-15
• Study Type: interventional
• Target: N/A
• Locations: 3 countries
• Sites: 24

Brief Summary

The primary objective of this study is to investigate the effect of 4-week treatment with 7.5 mg b.i.d, 15 mg q.d and 15 mg b.i.d. BIBW 2948 BS and placebo on cough and sputum as determined by the CASA-Q (Cough and Sputum Assessment Questionnaire

Conditions

Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic

Outcome Measures

Primary Outcomes (1)

• The primary endpoint of this study will be change in the Cough and Sputum PRO symptom domain scores from baseline (Visit 2) to the end of the 4 weeks treatment period.

  4 weeks

Secondary Outcomes (1)

• Cough and Sputum PRO symptom domain scores Cough and Sputum PRO impact domain scores 24 hours sputum wet/dry weight and volume Cough frequency as recorded by electronic recording of thorax movement Interleukin 8 P. Level Cough and Sputum Rating Sc

  4 weeks

Interventions

BIBW 2948 BS DRUG

7.5 mg b.i.d, 15mg q.d, 15mg b.i.d

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
• Male or female patients 40 years of age or older.
• Patients must have a diagnosis of COPD defined by a post-bronchodilator FEV1 \< 80% of predicted and FEV1 \< 70% of FVC (to be obtained 30 minutes after administration of salbutamol HFA). Predicted normal values will be calculated according to ECSC (R94-1408).
• For Height measured in inches
• Males:
• FEV1 predicted (L) = 4.30 x (height (inches)/39.37) - 0.029 x age (yrs) - 2.49
• Females:
• FEV1 predicted (L) = 3.95 x \[height (inches)/39.37\] - 0.025 x age (yrs) - 2.60
• or Height measured in meters
• Males:
• FEV1 predicted (L) = 4.30 x \[height (meters)\] - 0.029 x age (yrs) - 2.49
• Females:
• FEV1 predicted (L) = 3.95 x \[height (meters)\] - 0.025 x age (yrs) - 2.60
• Patients must have a diagnosis of chronic bronchitis symptoms i.e., cough and sputum expectoration on most days for at least three months in each of two consecutive years.
• Patients must be a current or ex-smoker with a smoking history of sup or egal to 10 pack years (Patients who have never smoked cigarettes must be excluded).

You may not qualify if:

• Patients with an acute or chronic hepatitis or alpha one antitrypsin deficiency or other liver disease.
• Patients with an aspartate aminotransferase (AST), alanine aminotransferase (ALT) 1.5 x the upper limit of the normal range will be excluded regardless of the clinical condition. A repeat laboratory evaluation will not be conducted in these patients.
• Patients with history of asthma or allergic rhinitis.
• Patients with history of post-nasal drip the last 3 months prior visit 1.
• Patients with a clinical diagnosis of bronchiectasis.
• Patients currently treated with expectorants and/or mucolytics drug.
• Patients taking medications with known cough promoting side effects (e.g., angiotensin converting enzyme inhibitors or angiotensin II receptor blockers) that in the opinion of the investigator are causing symptoms of cough.
• Patients with any respiratory tract infection or COPD exacerbation in the 30 days prior the visit 1 or during the 1-week period prior to visit 2 (visit 2 will not be postponed and the patient will be discontinued from the study).
• Patients who have had any change in their respiratory medications within the last 6 weeks prior the visit 1.
• Patients with a history of gastroesophageal reflux disease that have changed medication (dose intensification or a change in therapy) to treat this disease within the 6 weeks prior the visit 1.
• Patients with a history of cancer, other than treated basal cell carcinoma, within the last five years.
• Women of childbearing potential or who have not been post-menopausal for a duration for at least 2 years and have not had a hysterectomy or tubal ligation procedure.
• Participation in another trial with an investigational drug within 30 days or 6 half lives (whichever is greater) of the start of the study.
• A known hypersensitivity to lactose or any other component of the inhalation capsule or any other components of the inhalation capsule delivery system.
• Patients who are currently in a pulmonary rehabilitation program or who have completed a pulmonary rehabilitation program within four weeks prior the visit 1.

Sponsors & Collaborators

• Boehringer Ingelheim: lead

Study Sites (24)

1219.4.01001 Boehringer Ingelheim Investigational Site

Birmingham, Alabama, United States

Location

1219.4.01007 Boehringer Ingelheim Investigational Site

Phoenix, Arizona, United States

Location

1219.4.01006 Boehringer Ingelheim Investigational Site

Fort Collins, Colorado, United States

Location

1219.4.01002 Boehringer Ingelheim Investigational Site

Stamford, Connecticut, United States

Location

1219.4.01008 Boehringer Ingelheim Investigational Site

Rincon, Georgia, United States

Location

1219.4.01003 Boehringer Ingelheim Investigational Site

Greenville, South Carolina, United States

Location

1219.4.01004 Boehringer Ingelheim Investigational Site

Spartanburg, South Carolina, United States

Location

1219.4.01005 Boehringer Ingelheim Investigational Site

Union, South Carolina, United States

Location

1219.4.3306A Boehringer Ingelheim Investigational Site

Béthune, France

Location

1219.4.3306B Boehringer Ingelheim Investigational Site

Béthune, France

Location

1219.4.3302A Boehringer Ingelheim Investigational Site

Marseille, France

Location

1219.4.3303A Boehringer Ingelheim Investigational Site

Montpellier, France

Location

1219.4.3308A Boehringer Ingelheim Investigational Site

Nice, France

Location

1219.4.3307A Boehringer Ingelheim Investigational Site

Nîmes, France

Location

1219.4.3307B Boehringer Ingelheim Investigational Site

Nîmes, France

Location

1219.4.3301A Boehringer Ingelheim Investigational Site

Paris, France

Location

1219.4.3305A Boehringer Ingelheim Investigational Site

Toulouse, France

Location

1219.4.3305B Boehringer Ingelheim Investigational Site

Toulouse, France

Location

1219.4.49003 Boehringer Ingelheim Investigational Site

Eisenach, Germany

Location

1219.4.49004 Boehringer Ingelheim Investigational Site

Hamburg, Germany

Location

1219.4.49001 Boehringer Ingelheim Investigational Site

Hanover, Germany

Location

1219.4.49006 Boehringer Ingelheim Investigational Site

Mainz, Germany

Location

1219.4.49005 Boehringer Ingelheim Investigational Site

Rodgau-Dudenhofen, Germany

Location

1219.4.49002 Boehringer Ingelheim Investigational Site

Rüdersdorf, Germany

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Bronchitis, Chronic

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Bronchitis; Respiratory Tract Infections; Infections; Bronchial Diseases

Study Officials

• Boehringer Ingelheim

  Boehringer Ingelheim

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: July 30, 2008
• First Posted: August 1, 2008
• Study Start: August 1, 2008
• Primary Completion: September 1, 2008
• Last Updated: March 27, 2014

Record last verified: 2014-03

Locations

US (8); DE (6); FR (10)